Skip to Main Content

Paper Details

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors.
Int Immunopharmacol
6
2023
PD-1, PD-L1, Programmed cell death protein-1, ligand 1, malignant tumors, tumor, tumors
Author NameAffiliation
Ni LiuDepartment of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Jingyi TangDepartment of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
  • 1 - 2

Datasets

Release 1.2